2566 — Hangzhou Jiuyuan Genetic Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$1.84bn
- HK$1.28bn
- CNY1.31bn
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says JY54 Injection Obtains NMPA Approval To Conduct Clinical Trials In China
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says JY47 Injection IND Application Obtains Clinical Trial Approval From NMPA
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says Marketing Application For Jikeqin Accepted By NMPA
Novo Nordisk cuts price of weight-loss drug Wegovy in China (updated)
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical To Repurchase Up To 10.9 Million H Shares
Chinese doctors call for insurance coverage for weight-loss drugs
Chinese doctors call for insurance coverage for weight-loss drugs
Analysis: Innovent's weight-loss drug highlights China challenge for Novo, Lilly
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says Marketing Registration Of Jilixin Approved By NMPA
Brief: Hangzhou Jiuyuan Gene Engineering Says Marketing Registration Of Jixinfen Approved By NMPA